Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


The role of cytokines in the pathogenesis and treatment of HIV infection.

Catalfamo M, Le Saout C, Lane HC.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):207-14. doi: 10.1016/j.cytogfr.2012.05.007. Review.


Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Reuter MA, Pombo C, Betts MR.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):181-91. doi: 10.1016/j.cytogfr.2012.05.005. Review.


The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.

Lebouché B, Jenabian MA, Singer J, Graziani GM, Engler K, Trottier B, Thomas R, Brouillette MJ, Routy JP.

Trials. 2014 Oct 7;15:390. doi: 10.1186/1745-6215-15-390.


Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy.

Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB.

J Infect Dis. 2013 Jul 15;208(2):249-59. doi: 10.1093/infdis/jit147.


Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.

Poizot-Martin I, Faucher O, Obry-Roguet V, Nicolino-Brunet C, Ronot-Bregigeon S, Dignat-George F, Tamalet C.

J Clin Virol. 2013 Aug;57(4):351-5. doi: 10.1016/j.jcv.2013.04.007.


Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration..

PLoS One. 2013 Oct 30;8(10):e77665. doi: 10.1371/journal.pone.0077665.


Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.

Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.

J Immunol. 2005 Aug 1;175(3):2010-7.


Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM.

PLoS One. 2012;7(1):e30306. doi: 10.1371/journal.pone.0030306.


CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, Adelsberger J, Baseler M, Maldarelli F, Davey R, Roby G, Rehm C, Lane C.

J Immunol. 2011 Feb 15;186(4):2106-16. doi: 10.4049/jimmunol.1002000.


T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness.

Downey JS, Attaf M, Moyle G, Gazzard B, Gotch F, Imami N.

AIDS. 2011 Oct 23;25(16):1981-6. doi: 10.1097/QAD.0b013e32834b35a9.


Activation and lysis of human CD4 cells latently infected with HIV-1.

Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, Chen X, O'Dell S, Todd JP, Kwong PD, Rao SS, Yang ZY, Koup RA, Mascola JR, Nabel GJ.

Nat Commun. 2015 Oct 20;6:8447. doi: 10.1038/ncomms9447.


Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.


Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection.

Sester M, Sester U, Köhler H, Schneider T, Deml L, Wagner R, Mueller-Lantzsch N, Pees HW, Meyerhans A.

AIDS. 2000 Dec 1;14(17):2653-60.


The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.

Vandergeeten C, Fromentin R, Chomont N.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):143-9. doi: 10.1016/j.cytogfr.2012.05.001. Review.


Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452.


T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy.

Cossarizza A, Bertoncelli L, Nemes E, Lugli E, Pinti M, Nasi M, De Biasi S, Gibellini L, Montagna JP, Vecchia M, Manzini L, Meschiari M, Borghi V, Guaraldi G, Mussini C.

PLoS One. 2012;7(12):e50728. doi: 10.1371/journal.pone.0050728.


Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, Bandera A, Capetti A, Rizzardini G, Clerici M.

AIDS. 2010 Aug 24;24(13):1991-2000. doi: 10.1097/QAD.0b013e32833c93ce.


Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.

Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8. doi: 10.1097/QAI.0b013e318285cd33.


HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane HC.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19851-6. doi: 10.1073/pnas.0810032105.

Supplemental Content

Support Center